NEW YORK, May 27 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced that the Company has been invited to present its adult stem cell technologies at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York City on June 1, 2010. SCIENCE is designed to bring together investors with industry executives, visionary researchers and clinicians and other stakeholders to highlight opportunities and discuss advances in the stem cell field.
Alan Harris, M.D., Ph.D., NeoStem's VP of Regenerative Medicine, Drug Development and Regulatory Affairs, has been selected to participate in the 11:30 am ET panel discussion on "Adult versus Embryonic" stem cells. Dr. Harris will highlight the positive attributes of and advances in adult stem cell research, as well as discuss the regenerative properties of very small embryonic-like stem cells without the controversy of traditional embryonic stem cells. The panel will be moderated by Martin Grumet, Ph.D., Professor of Cell Biology and Neuroscience, Division of Life Sciences, at Rutgers University. Additional panel participants will include Michael West, Ph.D., CEO of BioTime, Inc., and Michael Schuster, VP of Operations at Angioblast System, Inc.
At a 2:00 pm ET plenary session, Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors, will be a key speaker discussing "Autologous Approaches" to stem cell therapy, including the Company's experience as a pioneer in the field of autologous (one's own) adult stem cell banking and its potential applications for future therapies. Other speakers at this session will include Ronnda Bartel, Ph.D., the CSO of Aastrom Biosciences, Inc., Eldad Melamed, M.D., CMO of Brainstorm Cell Therapeutics and Madhusudan Peshwa, Ph.D., Executive VP of Cellular Therapies at MaxCyte, Inc.
Additionally, at 2:45 pm ET, Reverend Tomasz Trafny of the Vatican's Pontifical Council for Culture will be a keynote speaker at the conference to discuss the Church's growing support of the scientific and medical application of autologous adult stem cell and discuss the bioethical considerations. NeoStem and the Pontifical Council for Culture recently announced a joint initiative that unites their charitable organizations to expand research and raise awareness of adult stem cell therapies, including working on multiple collaborative activities to advance scientific research on adult stem cells, exploring their clinical application in the field of regenerative medicine and the cultural relevance of such a fundamental shift in medical treatment options.
"We are excited about another opportunity to highlight NeoStem's industry leading effort in the adult stem cell field, particularly with the recently announced joint initiative with the Pontifical Council for Culture," said Dr. Smith.
Stem Cell Investor & Executive Networking Conference Event (SCIENCE)
SCIENCE is hosted by National Securities Corporation and MD Becker Partners. The SCIENCE program is strategically designed to unite investors with industry executives to exchange information and highlight opportunities in the expanding stem cell universe. The event will bring together the founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to offer compelling presentations, share information, and discuss the future of the exciting field.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful application of the Company's technology, including VSELTM technology, to develop adult stem cell therapies, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 and the Company's Quarterly Report on Form 10-q filed with the Securities and Exchange Commission on May 17, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: email@example.com Web: http://www.neostem.com CCG Investor Relations, Inc. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com Crocker Coulson, President Phone: +1-646-213-1915 Email: email@example.com
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved